Isofol Medical

0,67 SEK

-0,74 %

Mindre end 1K følgere

ISOFOL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Dividend

Investorkonsensus

Sammenligne

-0,74 %

+1,67 %

-6,94 %

-8,09 %

-3,67 %

-61,69 %

+16,76 %

-94,17 %

-95,03 %

Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, one of the world's most common cancers, where the medical need for better treatments is great.

Læs mere

Markedsværdi

214,73 mio. SEK

Aktieomsætning

288,67 t SEK

Omsætning

EBIT %

P/E

Udbytteafkast, %

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

19.5

2026

Generalforsamling '26

19.5

2026

Delårsrapport Q1'26

25.8

2026

Delårsrapport Q2'26

Alle

Selskabspræsentationer

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse15.4.2026, 14.00

Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)

Isofol Medical

Pressemeddelelse15.4.2026, 07.10

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

Isofol Medical

Selskabsmeddelelse10.4.2026, 06.00

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025

Isofol Medical

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Opret konto

Selskabsmeddelelse31.3.2026, 15.00

Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue

Isofol Medical

Selskabsmeddelelse18.3.2026, 12.50

Isofol secures license rights for arfolitixorin in autism

Isofol Medical

Selskabsmeddelelse13.3.2026, 17.40

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

Isofol Medical

Selskabsmeddelelse11.3.2026, 14.30

Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise

Isofol Medical

Selskabsmeddelelse9.3.2026, 10.00

Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director

Isofol Medical

Pressemeddelelse3.3.2026, 07.30

Isofol presents at investor meetings in March

Isofol Medical

Eksterne analyser25.2.2026, 06.22

Isofol Medical: From first lessons to second execution - ABG

* Strong early efficacy signal * Solid cost management * Fair value range of SEK 0.1-10.5/share Strong early efficacy signal Isofol today announced that all six currently evaluable RAS-mutated metastatic colorectal cancer patients in Part 1 of its Phase...

Isofol Medical

Selskabsmeddelelse24.2.2026, 08.32

Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin

Isofol Medical

Pressemeddelelse19.2.2026, 08.36

Redeye: Isofol Medical (Q4 Review): Translational year ahead

Isofol Medical

Selskabsmeddelelse18.2.2026, 06.30

Isofol Medical AB (publ) publishes year-end report, January – December 2025

Isofol Medical

Eksterne analyser15.1.2026, 12.46

Isofol Medical: Learn from the first, deliver on the second - ABG

* Targeting a huge unmet medical need * Revised best-in-class potential * Fair value range of SEK 0.1-10.5/share Huge unmet medical needIsofol is developing arfolitixorin, a next-generation active folate designed to enhance standard chemotherapy built...

Isofol Medical

Pressemeddelelse9.1.2026, 06.30

Isofol Medical

0,67 SEK

-0,74 %

Omsætning og EBIT-margin

EPS og udbytte

Finanskalender

Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025

Bliv en del af Inderes community

Inderes konto

Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue

Isofol secures license rights for arfolitixorin in autism

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise

Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director

Isofol presents at investor meetings in March

Isofol Medical: From first lessons to second execution - ABG

Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin

Redeye: Isofol Medical (Q4 Review): Translational year ahead

Isofol Medical AB (publ) publishes year-end report, January – December 2025

Isofol Medical: Learn from the first, deliver on the second - ABG

Isofol participates in the ASCO GI congress

BioStock: Back on track: 2025 was a year of clinical progress for Isofol, which restarted studies with arfolitixorin

Isofol participates in several investor meetings in December and January

BioStock: European Patent Office gives green light for Isofol’s arfolitixorin

BioStock: Isofol reaches new phase Ib/II milestones in Europe – prepares Japanese study with Solasia

European Patent Office intends to grant a new patent for Isofol’s arfolitixorin